Shots: The US FDA has accepted and granted PR to the sNDA of Xalkori for pediatric patients with r/r systemic ALCL that is ALK+. The FDA submission is based on P-I/II ADVL0912 study assessing the maximum dose & clinical activity of therapy with r/r solid tumors ALCL The submission is also supported by the A8081013 […]Read More
Shots: The P-1b/2 KEYNOTE-146/Study 111 trial involves assessing of Lenvima (20 mg/day) + Keytruda (200 mg IV q3w) in patients with NSCLC, Advanced melanoma & urothelial cancer P1b/2 KEYNOTE-146/Study 111 results: NSCLC: ORR 33.3%, mPFS 5.9 mos., mDOR 10.9 mos.; Advanced melanoma: ORR 47.6%, mPFS 5.5 mos., mDOR (12.5 mos.); Metastatic Urothelial Carcinoma: ORR 25%, […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
